<DOC>
	<DOCNO>NCT00005938</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DX-8951f treating patient biliary cancer .</brief_summary>
	<brief_title>DX-8951f Treating Patients With Biliary Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity DX-8951f term antitumor response , response duration , survival patient biliary tree cancer . II . Evaluate quantitative qualitative toxicity treatment regimen patient population . III . Evaluate pharmacokinetics DX-8951 plasma . OUTLINE : Patients receive DX-8951f IV 30 minute daily 5 day . Treatment repeat every 3 week least 2 course absence disease progression unacceptable toxicity . Patients follow every 3 month survival . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cholangiocarcinoma , bile duct cancer , gallbladder cancer without evidence unresectable extrahepatic metastasis Previously untreated disease OR Progressive disease first line chemotherapy Bidimensionally measurable disease CT scan , chest xray , MRI abdomen No known brain metastasis PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL Albumin least 2.8 g/dL SGOT SGPT great 5 time upper limit normal ( ULN ) PT INR great 1.5 time ULN ( Coumadin therapy ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study No concurrent serious infection No life threaten illness No overt psychosis mental disability would preclude informed consent No malignancy within past 5 year , except : Curatively treat nonmelanomatous skin cancer Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover No prior camptothecin analogues No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : At least 4 week since prior major surgery recover No concurrent surgery Other : No concurrent anticancer therapy At least 4 week since prior investigational drug No investigational drug within 4 week final dose study drug No concurrent drug induce inhibit CYP3A enzyme</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>localize gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>localize extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>liver intrahepatic biliary tract cancer</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>adult primary cholangiocellular carcinoma</keyword>
</DOC>